Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · USM201561018 US Manufacturing
Open in API
Filings indexed 379 across all filing types
Latest filing 2020-03-05 Capital/Financing Update
Country US United States of America
Listing US ENLV

About Enlivex Therapeutics Ltd.

https://www.enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage company developing macrophage reprogramming immunotherapy. Its primary focus is the development of Allocetra™, a universal, off-the-shelf cell therapy designed to rebalance immune hyper-responses. The therapy aims to modulate macrophages as a therapeutic strategy against inflammatory diseases. Enlivex is evaluating Allocetra™ for multiple indications, including acute inflammatory conditions like sepsis and chronic inflammatory diseases such as osteoarthritis. The product offers flexible administration options, including systemic intravenous infusion and targeted local injections, and has been administered in clinical trials to over 250 patients with no reported drug-related serious adverse events.

Recent filings

Filing Released Lang Actions
REPORT OF FOREIGN PRIVATE ISSUER
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filing by Enlivex Therapeutics Ltd., which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content details a securities purchase agreement, issuance of shares and warrants, placement agent fees, and related legal opinions. It is a regulatory filing to disclose a capital raising transaction and related agreements. The document is about a financing event and does not contain full financial statements or detailed financial performance data. It is not an annual or interim report, nor an earnings release or management discussion. The primary focus is on the capital raising transaction and related agreements, which fits the Capital/Financing Update category. The document length is 6394 characters, which is sufficient to contain substantive details about the financing. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2020-03-05 English
PROSPECTUS SUPPLEMENT
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a securities offering by Enlivex Therapeutics Ltd. It details the offering of ordinary shares and warrants, placement agent fees, use of proceeds, and other offering-specific information. The document is not a financial report, earnings release, management discussion, or regulatory filing in the typical sense but is a capital markets document related to fundraising. The presence of terms like 'offering price', 'placement agent', 'warrants', and 'securities' clearly indicates this is a capital/financing update. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2020-03-03 English
REPORT OF FOREIGN PRIVATE ISSUER
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by Enlivex Therapeutics Ltd., which is a report of a foreign private issuer submitted to the SEC. The content describes a securities purchase agreement and details of a registered direct offering, including the issuance of shares and warrants, fees paid to the placement agent, and intended use of proceeds. It includes exhibits such as the securities purchase agreement, placement agent warrant, legal opinions, and a press release. The document is not a full financial report but rather an update on capital raising activities. The Form 6-K is typically used for current reports by foreign private issuers to disclose material events. Given the focus on the issuance and sale of shares and warrants, this fits the category of a Capital/Financing Update rather than an annual report, earnings release, or other categories. The document length is 5708 characters, which is sufficient to contain substantive information about the financing event. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2020-02-26 English
PROSPECTUS SUPPLEMENT
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus supplement filed pursuant to Rule 424(b)(5) related to a securities offering by Enlivex Therapeutics Ltd. It includes information about the offering of ordinary shares and placement agent warrants, pricing, use of proceeds, risk factors, and other offering details. The document is a formal registration and offering document related to capital raising activities, not a financial report, earnings release, or management discussion. It is not an announcement of a report but the actual offering document. Therefore, it fits the category of Capital/Financing Update (CAP).
2020-02-26 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC. It contains a press release about the company's plan to increase manufacturing capacity related to COVID-19 treatment. The document is relatively short (2295 characters) and primarily serves as a regulatory announcement of a press release rather than a detailed financial report or earnings release. It does not contain financial statements or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-02-24 English
AMENDMENT NO. 3 TO SCHEDULE 13G
Major Shareholding Notification
2020-02-14 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.